Assessment against M/s. Cyanumtd

2033. CHOWDHARY RAM SEWAK: Will the Minister of INDUSTRY be pleased to state:

(a) what is the quantity of each of ins bulk drugs involved on which the amount has been assessed against Cyanamid along with the name of bulk drug and at what rate the amount has been recovered;

(b) what are the details of formulations based on each of the bulk, drug and what is the amount that has been assessed on each of the formulations;

(c) what are the packs and strengths: of each formulations involved and what was the quantity of each taken along with the rate at which the amount has been assessed;

(d) whether it is a fact that the comr pany represented against the assessment;

(e) if so, what are the contents of the representation and what action has been taken;

(f) whether any other company also submitted any representation; and

(g) if so, what are the details thereof?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (g) The required details in the question are quite voluminous. The til oe & efforts required for collection of these details will not be commensurate with the results likely to be achieved. However the representations made by the company were taken into account by the special team before finalising the report.

Overcharging on formulations

2034. DR. G. VIJAYA, MOHAN REDDY: Will the Minister of INDUSTRY be pleased to refer to the answer to Un-starred Question 965 given in the Rajya Sabha on the 25th November, 1985 and state:

(a) whether it is a fact that instances of overcharging the consumer on the formulations of Doxycycline, Ethambutol, Tetracycline Hcl., Dextropropoxyphene and Pyrental Pamoate came to the notice of his Ministry;

(b) if so, the names of the formulators to whom notices were sent on the above mentioned formulations;

(c) the names of the companies from whom his Ministry got the details in respect to procurement price and sales turnover of each unit;

(d) whether his Ministry has worked out the amount overcharged by these companies; and

(e) if so, names of the companies, amount overcharged by each and amount recovered from each during the last three years?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) Instances have come to the notice of the Government that amounts are recoverable under para 7(2) of DPCO, 1979 in respect of certain drugs.

(b) to (e) The amounts assessed for recovery have beeen disputed in a number of cases on various counts. It has been decided to refer this matter to a high powered committee.

Marketing of Dextropropoxyphene combinations

2035. DR. G. VIJAYA MOHAN, REDDY: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 3351 given in the Rajya Sabbsi on the 22nd August, 1988 and state:

(a) whether it is a fact that Dextropropoxyphene combinations are being marketed by the Wockhardt from the very beginning without price approval;

(b) whether it is also a fact that the company has by passed the law on one pretext or the other from the very beginning;

(c) since when they are indulging in this practice and how many times they have

been issued showcause notices and whether his Ministry failed to ensure compliance with the Price Axed;

(d) what are the full details and wojuld the matter be investigated in details; and

(e) what was the price fixed for each combination and what is the price for which this is being marketed?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (e) Combination formulation of Dextropropoxyphene and Paracetamol marketed by M/s. Wockhardt Limited are manufactured by M/s. Ultim Pharmaceuticals, an SSI unit. Prices of these formulations have been fixed under DPCO, 1987 as per details given in the enclosed statement.

Statement

Sl.No.	Name of the Formulation	Pack size	Retail Price (Rs.)
1	Proxyvon Capsules	6's	3·64
2	Proxyvon Capsules	500's	271·17
3	Butaproxyvon Capsules	6's	3·52
4	Spasmoproxyvon Capsules	6's	3·85

Overcharging on Dexrropropoxyphene Hcl

2036. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that since his Ministry has not enforced the notified price of Dextropropoxyphene Hcl, the formula tions based on this drug are being sold without price approval;

(b) how much price is being over-charged by the leading brands and what is the total amount being over-charged;

(c) whether it is a fact that this amount runs into crores of rupees yet no action has been taken against the producers; and

(d) if so, what steps have been taken by Government to fix the responsibility in such cases?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (d) An instance of Proxyvon range of formulations based on bulk drug Dextropropoxy-phene being marketed without price approval under DPCO, 1987, had recently ccnn to the notice of the Government. A show cause notice has been issued to the concerned company. Prices of various packs of these formulations have already been fixed under DPCO 1987.

Prices of Vitamin formulations

2037. SHRI CHANDRIKA PRASAD TRIPATHI: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 4603 given in the Rajya Sabha on 5th September, 1988 and state:

(a) what are the prices of Vitamin for mulations fixed for Sandoz and Pfizer under DPCO, 1979 and what were the prices being charged by the companies for their vitamin products; and

(b) what are the prices of Vitamin pro ducts of Pfizer fixed under DPCO, 1987?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) The details of prices fixed for various Vitamin formulations of M/s. Pfizer under DPCO, 1979 and DPCO, 1987 are given in reply to Unstarred Question 1421 answered on 21-11-1988. The details of prices fixed for multivitamin products of M/s. Sandoz (India) Ltd. under DPCO, 1979 are given in the attached statement *(See* below). The company had been charging their own price as per Orders of the Bombay High Court.